Pfizer (NYSE:PFE – Get Free Report) issued its earnings results on Tuesday. The biopharmaceutical company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.74 by $0.13, Zacks reports. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company had revenue of $16.58 billion for the quarter, compared to analyst estimates of $15.85 billion. During the same period in the previous year, the firm earned $0.87 EPS. The business’s revenue was down .4% on a year-over-year basis.
Pfizer Stock Performance
Shares of PFE opened at $30.90 on Tuesday. Pfizer has a 12-month low of $23.62 and a 12-month high of $31.06. The stock has a market cap of $176.14 billion, a P/E ratio of 40.45, a PEG ratio of 2.00 and a beta of 0.32. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. The company has a 50-day moving average of $28.60 and a two-hundred day moving average of $26.82.
Pfizer Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, November 6th. This represents a $1.72 dividend on an annualized basis and a yield of 5.6%. Pfizer’s payout ratio is presently 226.32%.
Analyst Ratings Changes
PFE has been the subject of several recent analyst reports. Cantor Fitzgerald raised their price objective on shares of Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research note on Thursday, October 8th. HSBC upped their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock a “hold” rating in a research report on Thursday, September 10th. Bank of America dropped their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Friday, July 10th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research report on Tuesday, October 13th. Finally, Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday, October 10th. Five research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and a consensus price target of $28.65.
Check Out Our Latest Stock Analysis on Pfizer
Key Pfizer News
Here are the key news stories impacting Pfizer this week:
- Positive Sentiment: Quarterly results exceeded expectations. Pfizer reported third-quarter adjusted earnings of $0.87 per share, above analyst estimates ranging from $0.72 to $0.74. Revenue of $16.58 billion also surpassed the approximately $15.85 billion consensus, although it was essentially flat year over year. Pfizer Surpasses Q3 Earnings and Revenue Estimates
- Positive Sentiment: Pfizer raised its full-year 2026 revenue and adjusted EPS outlook. Management cited strong year-to-date performance, cost reductions and commercial momentum. Demand for Eliquis, the company’s blood thinner, was specifically identified as a key driver. Pfizer Raises 2026 Forecast on Strong Demand for Eliquis
- Positive Sentiment: Growth is broadening beyond COVID products. Newly launched and acquired products reportedly grew 32% in the quarter, helping offset weaker vaccine and treatment sales and supporting the view that Pfizer’s pipeline and portfolio can generate post-pandemic growth. Pfizer Raises Forecast on Momentum With New Products
- Neutral Sentiment: Cecile Guegan was appointed permanent chief financial officer. The company veteran had served as interim CFO since August and brings familiarity with Pfizer’s finances and strategy, reducing transition risk but representing continuity rather than a major strategic change. Pfizer Appoints Cecile Guegan as Chief Financial Officer
- Negative Sentiment: Underlying revenue remains pressured. Third-quarter sales were down slightly from the prior year, and declining COVID-19 vaccine and treatment revenue continues to weigh on comparisons. Additionally, after a recent rally toward a 52-week high, some investors may question whether the earnings and guidance improvements are already reflected in the stock. Pfizer Just Gained 12 Percent in a Month
About Pfizer
Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.
The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.
Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.
Featured Stories
- Five stocks we like better than Pfizer
- Caterpillar’s Sell-Off: Is the Market Missing Its AI Power Play?
- Check Point’s Turnaround Could Be Closer Than Investors Think
- SpaceX Sent Verizon and T-Mobile Stocks Tumbling—Did Wall Street Overreact?
- SpaceX Starlink’s Telecom Ground Game Takes Shape
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
